Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Robust Armored Dual-Cytokine (IL-15/IL-21) GPC3-CAR T Cells for Atypical Teratoid Rhabdoid Tumors and Central Nervous System Rhabdoid Tumors (RADIANT)

NCT07513194 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT07513194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07513194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Robust Armored Dual-Cytokine (IL-15/IL-21) GPC3-CAR T Cells for Atypical Teratoid Rhabdoid Tumors and Central Nervous System Rhabdoid Tumors (RADIANT)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
October 31, 2044
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid rhabdoid tumor, central nervous system rhabdoid tumor